220 patents
Page 6 of 11
Utility
Oligonucleotide Mediated No-go Decay
18 Nov 21
The present disclosure provides oligomeric compounds comprising a modified oligonucleotide that induces no-go decay of a target mRNA.
Xue-hai Liang, Joshua Nichols, Stanley T. Crooke
Filed: 4 Oct 19
Utility
Compounds and Methods for Reducing Fxi Expression
18 Nov 21
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FXI RNA in a cell or subject, and in certain instances reducing the amount of FXI protein in a cell or subject.
Huynh-Hoa Bui
Filed: 8 May 19
Utility
Allele Specific Modulators of P23H Rhodopsin
11 Nov 21
The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject.
Susan F. Murray, Punit P. Seth, Michael L. McCaleb, Susan M. Freier, Priyam Singh
Filed: 21 May 21
Utility
GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
11 Nov 21
The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.
Brett P. Monia, Thazha P. Prakash, Garth A. KINBERGER, Richard Lee, Punit P. Seth, Shalini Andersson, Eva Carina Ämmälä, Daniel Laurent Knerr, Maria Astrid Ölwegård-Halvarsson, Eric Valeur, William John Drury, III
Filed: 15 Apr 21
Utility
Methods for Reducing LRRK2 Expression
4 Nov 21
Provided herein are methods for decreasing LRRK2 mRNA expression.
Hien Thuy Zhao, Holly Kordasiewicz
Filed: 17 Dec 20
Utility
Compounds and Methods for Modulation of Transcript Processing
14 Oct 21
Provided herein are methods, compounds, and compositions for modulation of transcript processing.
Thazha P. Prakash, Frank Rigo, Punit P. Seth
Filed: 18 Nov 20
Utility
Modulation of LNC05 Expression
23 Sep 21
Provided herein are methods, compounds, and compositions for reducing expression of lnc05 in a cell or individual.
Allen Tingjin Yu, David L. Spector, Frank Rigo, Susan M. Freier, Jan Bergmann, Carmen Berasain
Filed: 3 Jun 21
Utility
Method of Conjugating Oligomeric Compounds
16 Sep 21
Provided herein are solid phase methods for the synthesis of conjugated oligomeric compounds and intermediates used in such methods.
Isaiah E. Cedillo, Recaldo Carty
Filed: 6 Oct 17
Utility
Methods for Treating Hypercholesterolemia
16 Sep 21
Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C.
Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Diane Tribble, Sanjay Bhanot, Andrew T. Watt
Filed: 25 Sep 20
Utility
Methods for Safely Reducing Thrombopoietin
9 Sep 21
Provided herein are methods, compounds, and compositions for safely reducing thrombopoietin in a cell or an individual.
Andras Gruber, Erik Tucker, Brett P. Monia, Alexey Revenko
Filed: 16 Jul 19
Utility
Compounds and Methods for Modulating UBE3A-ATS
9 Sep 21
Susan M. Freier, Huynh-Hoa Bui, Paymaan Jafar-nejad, Frank Rigo
Filed: 21 Apr 21
Utility
Compositions and Methods for Modulating PKK Expression
9 Sep 21
Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
Filed: 11 May 20
Utility
Compounds and Methods for the Modulation of Proteins
2 Sep 21
In certain embodiments, the present disclosure provides compounds and methods of increasing the amount or activity of a target protein in a cell.
Stanley T. Crooke, Xue-hai Liang, Wen Shen
Filed: 15 Sep 20
Utility
Modified Compounds and Uses Thereof
26 Aug 21
The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications.
Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
Filed: 10 Feb 21
Utility
Linkage Modified Oligomeric Compounds
19 Aug 21
The present invention provides gapped oligomeric compounds comprising from 1 to about 3 internucleoside linkages having one of formulas I to XVI.
Michael T. Migawa, Eric E. Swayze, Punit P. Seth
Filed: 17 Jun 19
Utility
Compounds and Methods for Increasing STMN2 Expression
19 Aug 21
Provided are compounds, methods, and pharmaceutical compositions for increasing the amount or activity of STMN2 RNA in a cell or animal, and in certain embodiments increasing the amount of STMN2 protein in a cell or animal.
Huynh-Hoa Bui, Don W. Cleveland, Ze'ev Melamed
Filed: 14 Jun 19
Utility
Selective Antisense Compounds and Uses Thereof
5 Aug 21
The present invention provides oligomeric compounds.
Punit P. Seth, Michael Oestergaard, Eric E. Swayze
Filed: 3 Sep 20
Utility
Compositions for Modulating C9ORF72 Expression
29 Jul 21
Disclosed herein are compositions and methods for reducing expression of C9ORF72 mRNA and protein in an animal.
Frank Rigo
Filed: 18 Sep 20
Utility
Compositions for Modulating Expression of C9ORF72 Antisense Transcript
15 Jul 21
Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors.
Frank Rigo
Filed: 27 Aug 20
Utility
Compositions and Methods for Modulating Growth Hormone Receptor Expression
8 Jul 21
The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Sanjay Bhanot, Susan M. Freier, Huynh-Hoa Bui
Filed: 4 Aug 20